Business
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
Independent DSMB has identified no safety concerns, and recommends continuation of BriaCellȁ...
About this update from Briacell Therapeutics Corp
[{"type":"text","content":"BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer\n\n\n\n\n\n\n Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor\n \n\n\n\n\n\n Fourth consecutive positive DSMB recommendation supports the favorable safety profile observed to date\n \n\n\n\n\n\n Phase 3 study is being conducted under FDA Fast Track Designation, reflecting the significant unmet need in metastatic breast cancer\n \n\n\n\n\n\n PHILADELPHIA and VANCOUVER, British Columbia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the independent Data Safety Monitoring Board (DSMB) has issued its fourth consecutive positive recommendation following review of safety data from BriaCell’s pivotal Phase 3 study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer (\n \n NCT06072612\n \n ).\n \n\n Following its review, the DSMB raised no safety concerns and recommended that the study continue without modifications. DSMB meetings occur quarterly in accordance with the study protocol. BriaCell’s ongoing pivotal Phase 3 study is being conducted under Fast Track designation granted by the US Food and Drug Administration (FDA), reflecting the significant unmet medical need in metastatic breast cancer.\n \n\n “Repeated consecutive DSMB positive recommendations further strengthen our confidence in the excellent safety and tolerability profile of the BriaCell regimen,” commented Dr. William V. Williams, BriaCell’s President & CEO. “We strongly believe in Bria-IMT’s potential to transform cancer care and remain determined to make it a reality for patients with metastatic breast cancer who face urgent medical needs.”\n \n\n\n About BriaCell Therapeutics Corp.\n \n\n\n BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at\n \n https://briacell.com/\n \n .\n \n\n\n Safe Harbor\n \...